SANOFI
Sanofi is the result of the merger of several French laboratories, including Synthélabo, Aventis – which emerged from the combination of Rhône-Poulenc and Hoechst – and the pharmaceutical activities of Sanofi-Synthélabo. The group is a global player in health and biotechnology, active in rare diseases, vaccines, and consumer healthcare. It has distinguished itself through major advancements such as glargine insulin (Lantus), a reference treatment for diabetes, and iconic vaccines against poliomyelitis, rabies, and influenza developed by Sanofi Pasteur. Sanofi invests in biotechnology research and the global production of vaccines, contributing to prevention and international health security.
Anantys Community
10 members hold SANOFI with an average return of -1.3%. Join them to follow signals and build your long-term investment strategy.
Price history of SANOFI
Price history of SANOFI
Performance & Momentum
Sanofi bets on AI and rare diseases
Sanofi is strengthening its growth strategy by expanding its artificial intelligence center of excellence in Toronto. The group aims to speed up drug and vaccine research, development and manufacturing through more advanced digital tools, while also focusing on detecting rare diseases such as alpha-1 antitrypsin deficiency. These initiatives point to an upgrade in its innovation capabilities and could support its medium-term outlook by improving the efficiency of its R&D programs and strengthening its positioning in rare diseases. For Sanofi shares, the announcement is being viewed fairly positively, even if the immediate financial impact remains limited.
Strategic Analysis
SANOFI • 2026
Sanofi is a major global pharmaceutical company with significant exposure to specialty medicines, vaccines, and consumer healthcare. Its positioning is based on a diversified portfolio, a long-standing strong presence in diabetes, and the ability to monetize defensive franchises over the long term, while maintaining an income profile appreciated by investors.
- Leading position in several defensive healthcare segments, with a global commercial footprint
- Exposure to attractive and recurring areas such as diabetes, vaccines, and certain rare diseases
- Value profile supported by a tradition of regular dividend payments
- Growth is sometimes seen as less dynamic than that of some major biotechnology or innovative healthcare stocks
- Sensitivity to portfolio renewals and the success of clinical research, with execution risk on new growth drivers
Momentum appears solid but still mixed in light of the recent share price trend: the underlying trend remains constructive, without fully offsetting a period of pressure on medium-term performance. For an investor, this reflects a high-quality defensive name that could become more attractive again if growth and pipeline catalysts confirm the group's potential.
Similar stocks to SANOFI
Often held with SANOFI
Recent News
SANOFI
Sanofi may review portfolio under new CEO
3 weeks agoAhead of Belén Garijo's arrival, Sanofi is hinting that it could review its drug portfolio and expand into new therapeutic areas. The announcement comes after the group already signaled higher sales at the start of the year, giving the update a constructive tone, even if the 2.05% daily decline shows a somewhat cautious market reaction.
Sanofi Boosts Vaccine Presence in Canada
1 month agoSanofi says it has become the market authorization holder for Nuvaxovid in Canada. Taking control of Novavax’s non-mRNA vaccine broadens the group’s offering in respiratory vaccines and could gradually support sales in the region, especially ahead of the 2026-2027 season. The news is broadly positive for Sanofi, which continues to build a diversified vaccine portfolio and expand its presence in a strategic market. The short-term market impact is likely to remain limited, however, as the announcement is more of a commercial strengthening than an immediate financial catalyst.
Sanofi faces Dupixent patent expiry in 2031
2 months agoThe article highlights growing concern among Sanofi executives as 2031 approaches, the year the patent protecting the flagship drug Dupixent will expire. This milestone could weaken the group's growth prospects, especially since current R&D investments are not leading to significant new drivers. The stock remains stable in the short term, reflecting cautious market anticipation.
Sanofi Completes Acquisition of Dynavax
3 months agoOn February 10, 2026, Sanofi announced the completion of its acquisition of Dynavax Technologies, strengthening its portfolio in vaccines and immunotherapies. This move could boost the group's medium-term prospects, although the market reaction remains neutral despite a recent 4.19% dip, likely due to profit-taking or post-announcement volatility.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
